NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05941520 2026-04-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-04-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06195306 2026-04-13
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06434064 2026-03-02
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06348134 2026-02-17
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Phase 2 Recruiting
NCT05501704 2026-01-07
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05035836 2025-12-22
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06364267 2025-11-18
BabyTears
Ente Ospedaliero Ospedali Galliera
Phase 2 Recruiting
NCT06361940 2025-10-14
MAPPER
Medical College of Wisconsin
Phase 2 Recruiting
NCT02476786 2025-07-28
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
Phase 2 Recruiting
NCT04765098 2025-06-26
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT05472792 2025-05-23
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06914674 2025-04-06
SPTP
Fudan University
Phase 2 Recruiting
NCT04985266 2024-12-05
TRAK-ER
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT04666961 2022-04-22
HORNEO01
Institut Cancerologie de l'Ouest
Phase 2 Recruiting